Arbutus Biopharma Corp (ABUS) research
Arbutus Biopharma Corp- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $4.67
- As of
Kresmion compiles this page from ABUS's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Arbutus Biopharma Corp (ABUS): 3 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-21.
As of . Source: SEC EDGAR filings for ABUS. Method and limitations.
Share the ABUS intelligence card
See the full ABUS dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for ABUS on one page. Preview it with sample data, then open it live with a free account.
Preview the ABUS dossierActive signals for ABUS
- highACTIVIST_STAKE
Activist 13D filing, dividend
- highCONSENSUS_BUY
3 tracked funds increased ABUS this 2026Q2, institutional consensus
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +809% to ABUS (2026Q2)
- highINSTITUTIONAL_SURGE
D. E. Shaw & Co., Inc. added +167% to ABUS (2026Q2)
- mediumNEW_POSITION
TWO SIGMA INVESTMENTS, LP new position in ABUS
FREE, NO ACCOUNT
Every signal on ABUS, as it fires
You are seeing 5 of 10 signals recorded on ABUS since 2026-05-16.
The five above landed across 2 days. The other 5 were recorded on 2 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in ABUS (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 03879J100 · 2026Q2 | $1.9M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 03879J100 · 2026Q2 | $1.8M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 03879J100 · 2026Q2 | $408K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, ABUS
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
ABUS against its peers
ABUS's operating margin of -271.0% ranks in the 39th percentile of 8 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | ABUS | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 14.1M USD | 67.5M USD | 35 | 9 |
| Operating margin | -271.0% | -71.0% | 39 | 8 |
| Net margin | -237.9% | -66.2% | 39 | 8 |
| Return on equity | -43.7% | -38.3% | 47 | 17 |
Peers (18): ARDX, TBPH, RIGL, JBIO, GLUE, SANA, SGP, KURA, CGEM, LXRX, AVTX, CRVS, ACHV, ANNX, MLTX, DSGN, GERN, JANX. Left out: IVA (period gap), APMD (no annual filing), HELP (period gap), OBX (no annual filing), ATTO (no annual filing), ANL (period gap), SPTX (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (ABUS: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow ABUS on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to ABUS for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.